AVIRAtea Pharmaceuticals, Inc.
Pharmaceutical Preparations
- Revenue
- —
- Operating margin
- —
- EBITDA
- −$180M
- 6.3% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear6% of revenueOver 10% of revenue
- Payouts exceed cash flowClear-19% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $351M | — | — | — | — | |
| Operating income | $138M | −$131M | −$164M | −$193M | −$181M | 6.3% |
| Net income | $121M | −$116M | −$136M | −$168M | −$158M | 6.0% |
| Operating cash flow | −$87M | −$121M | −$85M | −$135M | −$132M | 2.6% |
| Capex | $4K | $2M | — | — | — | |
| Stock-based comp | $40M | $47M | $49M | $52M | $21M | 60% |
| Buybacks | — | — | — | $0 | $26M |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $3M | $4M | 9 | 125 |
| FY2024 | $4M | $4M | 8 | 93 |
| FY2023 | $6M | $3M | 7 | 94 |
| FY2022 | $6M | $705K | 12 | 90 |
| FY2021 | $34M | −$1M | 21 | 100 |